Zoetis (ZTS) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $78.42, +4.16% vs the prior close of $75.29.
- Volume 5.01M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ZTS jumps 4.2% to $78.42, a 3-month high. Closed at $78.42, +4.16% vs the prior close of $75.29. Day range $76.52–$79.15, opened at $76.70.
ZTS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ZTS jumps 4.2% to $78.42, a 3-month high
- Closed at $78.42, +4.16% vs the prior close of $75.29. Day range $76.52–$79.15, opened at $76.70.
- Volume was 5.01M shares, 1.0x its 50-day average of 5.25M.
- Price is +6.1% vs its 50-day average ($73.94) and -18.4% vs its 200-day average ($96.10).
- 52-week range $68.77–$148.30; today's close sits at 12% of that range, 47.1% below the 52-week high.
Oct 14, 2026 — ZTS rises 1.3% to $75.29
- Closed at $75.29, +1.33% vs the prior close of $74.30. Day range $74.25–$75.89, opened at $74.54.
- Volume was 4.16M shares, 0.8x its 50-day average of 5.32M.
- Price is +1.9% vs its 50-day average ($73.86) and -21.8% vs its 200-day average ($96.34).
- 52-week range $68.77–$148.30; today's close sits at 8% of that range, 49.2% below the 52-week high.
Oct 13, 2026 — ZTS dips 1.8% to $74.30
- Closed at $74.30, -1.78% vs the prior close of $75.65. Day range $74.28–$75.99, opened at $75.98.
- Volume was 3.30M shares, 0.6x its 50-day average of 5.36M.
- Price is +0.6% vs its 50-day average ($73.88) and -23.1% vs its 200-day average ($96.59).
- 52-week range $68.77–$148.30; today's close sits at 7% of that range, 49.9% below the 52-week high.
- SEC filings that day: 8-K.
Oct 12, 2026 — ZTS rises 1.1% to $75.65, a 1-month high, 4 up days in a row
- Closed at $75.65, +1.12% vs the prior close of $74.81. Day range $74.17–$75.69, opened at $75.00.
- Volume was 4.09M shares, 0.8x its 50-day average of 5.38M.
- Price is +2.3% vs its 50-day average ($73.93) and -21.9% vs its 200-day average ($96.85).
- 52-week range $68.77–$148.30; today's close sits at 9% of that range, 49.0% below the 52-week high.
- That makes 4 straight gains.
Oct 9, 2026 — ZTS rises 2.4% to $74.81, a 1-month high, 3 up days in a row
- Closed at $74.81, +2.37% vs the prior close of $73.08. Day range $73.00–$74.85, opened at $73.04.
- Volume was 2.91M shares, 0.5x its 50-day average of 5.41M — lighter than usual.
- Price is +1.1% vs its 50-day average ($73.97) and -22.9% vs its 200-day average ($97.09).
- 52-week range $68.77–$148.30; today's close sits at 8% of that range, 49.6% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — ZTS rises 2.1% to $73.08
- Closed at $73.08, +2.14% vs the prior close of $71.55. Day range $71.15–$73.75, opened at $71.36.
- Volume was 6.18M shares, 1.1x its 50-day average of 5.40M.
- Price is -1.2% vs its 50-day average ($73.99) and -24.9% vs its 200-day average ($97.33).
- 52-week range $68.77–$148.30; today's close sits at 5% of that range, 50.7% below the 52-week high.
- SEC filings that day: 8-K.
Oct 7, 2026 — ZTS rises 0.3% to $71.55
- Closed at $71.55, +0.31% vs the prior close of $71.33. Day range $71.12–$72.09, opened at $71.73.
- Volume was 4.13M shares, 0.8x its 50-day average of 5.44M.
- Price is -3.4% vs its 50-day average ($74.09) and -26.7% vs its 200-day average ($97.58).
- 52-week range $68.77–$148.30; today's close sits at 3% of that range, 51.8% below the 52-week high.
Oct 6, 2026 — ZTS ends flat (-0.1%) to $71.33
- Closed at $71.33, -0.11% vs the prior close of $71.41. Day range $70.59–$72.30, opened at $71.88.
- Volume was 3.43M shares, 0.6x its 50-day average of 5.44M.
- Price is -3.9% vs its 50-day average ($74.21) and -27.1% vs its 200-day average ($97.84).
- 52-week range $68.77–$148.30; today's close sits at 3% of that range, 51.9% below the 52-week high.
Oct 5, 2026 — ZTS rises 2.5% to $71.41
- Closed at $71.41, +2.47% vs the prior close of $69.69. Day range $69.00–$71.47, opened at $69.41.
- Volume was 3.64M shares, 0.7x its 50-day average of 5.47M.
- Price is -3.9% vs its 50-day average ($74.32) and -27.2% vs its 200-day average ($98.09).
- 52-week range $68.77–$148.79; today's close sits at 3% of that range, 52.0% below the 52-week high.
Oct 2, 2026 — ZTS rises 0.9% to $69.69
- Closed at $69.69, +0.85% vs the prior close of $69.10. Day range $68.77–$70.10, opened at $69.12.
- Volume was 5.26M shares, 1.0x its 50-day average of 5.49M.
- Price is -6.3% vs its 50-day average ($74.40) and -29.1% vs its 200-day average ($98.35).
- 52-week range $68.77–$148.79; today's close sits at 1% of that range, 53.2% below the 52-week high.
ZTS latest news & SEC filings
Every SEC filing by or about ZTS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Oct 8, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 6, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $2.47B (prior year $2.47B) (-0.2% vs Jun 30, 2025)
- Net income: $691.00M (prior year $726.00M) (-4.8% vs Jun 30, 2025)
- Diluted EPS: $1.65 (prior year $1.63) (+1.2% vs Jun 30, 2025)
Aug 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 22, 2026 · 11-K — Annual report for an employee stock plan
Annual report for an employee stock plan
Things to know before you trade ZTS
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 12, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.48% (largest 4.2%).
- Liquidity: about 4.42M shares (≈$346.45M) trade per day on average.
- 52-week position: $78.42 vs a range of $68.77–$148.30 (12% of the range).
- Dividends: last ex-dividend date Jul 20, 2026 ($0.53/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 3 open-market buys, 2 sales; latest: Frank A Damelio bought 6,650 shares on May 13, 2026.
- Latest filings: 8-K Oct 13, 2026; 8-K Oct 8, 2026; 8-K Aug 6, 2026.
- Share count: 413.22M shares outstanding (Jul 31, 2026), -6.8% vs a year earlier — the company has been reducing its share count.
- Listing: NYSE · industry: Pharmaceutical Preparations.
ZTS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 76.70 | 79.15 | 76.52 | 78.42 | 5.01M |
| Oct 14, 2026 | 74.54 | 75.89 | 74.25 | 75.29 | 4.16M |
| Oct 13, 2026 | 75.98 | 75.99 | 74.28 | 74.30 | 3.30M |
| Oct 12, 2026 | 75.00 | 75.69 | 74.17 | 75.65 | 4.09M |
| Oct 9, 2026 | 73.04 | 74.85 | 73.00 | 74.81 | 2.91M |
| Oct 8, 2026 | 71.36 | 73.75 | 71.15 | 73.08 | 6.18M |
| Oct 7, 2026 | 71.73 | 72.09 | 71.12 | 71.55 | 4.13M |
| Oct 6, 2026 | 71.88 | 72.30 | 70.59 | 71.33 | 3.43M |
| Oct 5, 2026 | 69.41 | 71.47 | 69.00 | 71.41 | 3.64M |
| Oct 2, 2026 | 69.12 | 70.10 | 68.77 | 69.69 | 5.26M |
| Oct 1, 2026 | 70.00 | 70.90 | 68.92 | 69.10 | 5.35M |
| Sep 30, 2026 | 70.55 | 70.77 | 69.52 | 69.83 | 4.44M |
| Sep 29, 2026 | 71.40 | 71.70 | 70.00 | 70.30 | 3.52M |
| Sep 28, 2026 | 70.50 | 71.68 | 70.08 | 71.43 | 3.91M |
| Sep 25, 2026 | 70.00 | 71.08 | 69.52 | 71.05 | 4.17M |
| Sep 24, 2026 | 71.85 | 72.38 | 69.93 | 70.27 | 3.37M |
| Sep 23, 2026 | 72.75 | 73.55 | 71.55 | 71.61 | 3.83M |
| Sep 22, 2026 | 71.98 | 73.46 | 71.24 | 72.86 | 3.84M |
| Sep 21, 2026 | 72.06 | 72.48 | 70.26 | 71.33 | 3.94M |
| Sep 18, 2026 | 72.57 | 73.05 | 71.40 | 71.40 | 9.87M |
About Zoetis
Zoetis (ZTS) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PARSIPPANY, NJ. Fiscal year ends December 31. SEC CIK 1555280.
ZTS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Paul Bisaro | Director | May 13, 2026 |
| Vanessa Broadhurst | Director | Feb 23, 2026 |
| Frank A Damelio | Director | Aug 11, 2026 |
| Gavin Hattersley | Director | Feb 23, 2026 |
| Antoinette Renee Leatherberry | Director | Feb 23, 2026 |
| Michael B Mccallister | Director | Jun 11, 2026 |
| Gregory Norden | Director | Mar 10, 2026 |
| Louise M Parent | Director | May 21, 2026 |
| Kristin C Peck | Chief Executive Officer | Jul 14, 2026 |
| Willie M Reed | Director | Feb 23, 2026 |
| Khosla Sanjay | Director | Feb 23, 2026 |
| Mark Stetter | Director | Sep 18, 2026 |
| Stephanie Tilenius | Director | Feb 19, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Nicholas Ashton | Executive Vice President | Feb 23, 2026 |
| Jamie Brannan | Executive Vice President | Feb 23, 2026 |
| Rimma Driscoll | Executive Vice President | Jul 14, 2026 |
| Kevin Esch | Executive Vice President | Jul 14, 2026 |
| Julie Fuller | Executive Vice President | Jul 14, 2026 |
| Astorga Jeannette Ferran | Executive Vice President | Jul 14, 2026 |
| Wetteny Joseph | Chief Financial Officer | Jul 14, 2026 |
| Roxanne Lagano | Executive Vice President | Jul 14, 2026 |
| Abhay U Nayak | Executive Vice President | Jul 14, 2026 |
| Kristin C Peck | Chief Executive Officer | Jul 14, 2026 |
| Robert J Polzer | Executive Vice President | Oct 14, 2025 |
| James Saccaro | EVP, CFO & COO | Sep 2, 2026 |
| Keith Sarbaugh | Executive Vice President | Jul 14, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 13, 2026 | Frank A Damelio | Buy | 6,650 | $75.39 |
| May 13, 2026 | Paul Bisaro | Buy | 2,000 | $75.88 |
| May 11, 2026 | Michael B Mccallister | Buy | 3,000 | $77.76 |
| Feb 17, 2026 | Kristin C Peck | Sale | 10,800 | $127.55 |
| Feb 17, 2026 | Kristin C Peck | Sale | 9,200 | $126.46 |
ZTS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $9.47B | $2.67B | 6.02 | $2.90B |
| Dec 31, 2024 | $9.26B | $2.49B | 5.47 | $2.95B |
| Dec 31, 2023 | $8.54B | $2.34B | 5.07 | $2.35B |
| Dec 31, 2022 | $8.08B | $2.11B | 4.49 | $1.91B |
| Dec 31, 2021 | $7.78B | $2.04B | 4.27 | $2.21B |
Latest balance sheet: total assets $15.08B, total liabilities $11.93B, cash $1.48B (as of Jun 30, 2026).
ZTS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $77.27 |
| May 7, 2026 | 8-K Item 2.02 (results) | $87.31 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $125.64 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $124.46 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $146.12 |
| May 6, 2025 | 8-K Item 2.02 (results) | $149.87 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $164.93 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $175.18 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 13, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ZTS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.